Literature DB >> 34238236

Validation of questionnaire-reported chest wall abnormalities with a telephone interview in Swiss childhood cancer survivors.

Rahel Kasteler1,2, Christa Lichtensteiger1, Christina Schindera1,3, Marc Ansari4,5, Claudia E Kuehni6,7.   

Abstract

BACKGROUND: Chest wall abnormalities are a poorly studied complication after treatment for childhood cancer. Chest wall abnormalities are not well-described in the literature, and little is known on the impact on daily life of survivors.
METHODS: We investigated prevalence and risk factors of chest wall abnormalities in childhood cancer survivors in a nationwide, population-based cohort study (Swiss Childhood Cancer Survivor Study) with a questionnaire survey. We then interviewed a nested sample of survivors to validate types of chest wall abnormalities and understand their impact on the daily life of survivors.
RESULTS: Forty-eight of 2382 (95%CI 2-3%) survivors reported a chest wall abnormality. Risk factors were older age at cancer diagnosis (16-20 years; OR 2.5, 95%CI 1.0-6.1), lymphoma (OR 3.8, 95%CI 1.2-11.4), and central nervous system tumors (OR 9.5, 95%CI 3.0-30.1) as underlying disease, and treatment with thoracic radiotherapy (OR 2.0, 95%CI 1.0-4.2), surgery to the chest (OR 4.5, 95%CI 1.8-11.5), or chemotherapy (OR 2.9, 95%CI 1.0-8.1). The nature of the chest wall abnormalities varied and included thoracic wall deformities (30%), deformations of the spine (5%) or both (55%), and scars (10%). Chest wall abnormalities affected daily life in two thirds (13/20) of those who reported these problems and necessitated medical attention for 15 (75%) survivors.
CONCLUSION: It is important that, during follow-up care, physicians pay attention to chest wall abnormalities, which are rare late effects of cancer treatment, but can considerably affect the well-being of cancer survivors.

Entities:  

Keywords:  Cancer treatment; Chest wall deformity; Late effects; Swiss Childhood Cancer Survivor Study

Year:  2021        PMID: 34238236      PMCID: PMC8268220          DOI: 10.1186/s12885-021-08425-z

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


Background

Chest wall abnormalities have been reported in a widely variable proportion of childhood cancer survivors. Available studies were small, including 16 to 143 participants [1-9], or focused on patients with selected cancer diagnoses only, e.g., chest wall sarcoma [1], central nervous system (CNS) tumours [10], neuroblastoma [2, 9], or Wilms tumour [3, 4]. Some studies reported on specific cancer treatments such as thoracic radiotherapy, radiotherapy to the spine [6], abdominal radiotherapy [7, 8], or surgical interventions for solid tumours [5]. Such studies are not representative of the entire population of childhood cancer survivors. In large, cross-sectional studies, 1.4% [11] (North America, multicenter study) to 2.0% [12] (Switzerland, population-based study) of survivors reported chest wall abnormalities in questionnaire surveys [10-12]. Those investigations used one single question on chest wall abnormalities, which did not enable understanding of the type of chest wall abnormalities as no exact definition was attached to the question. Survivors might not understand the term “chest wall abnormalities” in the way researchers intend. They might choose to report different health issues as chest wall abnormalities, including thoracic wall deformities, spinal deformities, breast asymmetries, or scars. No study investigated whether and how chest wall abnormalities affect the daily life of survivors and if medical care is needed. With this study, we wanted to expand the epidemiological knowledge on chest wall abnormalities in survivors. First, we assessed the prevalence of chest wall abnormalities reported by survivors in Switzerland and investigated cancer and cancer-treatment-related risk factors for chest wall abnormalities. Second, we interviewed a nested sample of survivors to validate and clarify the type of chest wall abnormalities reported by survivors and their impact on daily life. Last, we conducted a systematic review of the available literature on chest wall abnormalities in childhood cancer survivors.

Methods

Swiss childhood Cancer survivor study

The Swiss Childhood Cancer Survivor Study (SCCSS) is a population-based, long-term follow-up study of patients registered in the Swiss Childhood Cancer Registry (SCCR, www.childhoodcancerregistry.ch). Participants have been diagnosed with leukemia, lymphoma, CNS tumors, malignant solid tumors, or Langerhans cell histiocytosis after 1976 and before the age of 21 years. Participants, who have survived ≥5 years since initial cancer diagnosis and were alive at the time of the study, received a questionnaire between 2007 and 2013. Nonresponders received a second copy of the questionnaire four to 6 weeks later. If they again did not answer, we contacted them by phone. In total 2382 survivors replied (Supplementary figure S1). Detailed methods of the SCCSS have been published [12-14].

Outcome: chest wall abnormalities

The SCCSS questionnaire, like the North Amercian [15] and British [16] Childhood Cancer Survivor Studies, includes one question on chest wall abnormalities in the section on pulmonary health: “Have you ever been told by a doctor that you have or have had changes to your thorax and/or ribs?” and possible answers included ever in life (yes/no), since when (year), and currently (yes/no) (Supplementary figure S2).

Validation of outcome by telephone interview

In a nested follow-up study, we sent a letter to all survivors who had reported a chest wall abnormality in the questionnaire to invite them to take part in a telephone interview. All those were at least 18 years old, still alive, had consented to participation in further studies, and had a valid telephone number. Survivors were contacted by telephone between July 2017 and September 2017 by one investigator (CL) (Supplementary figure S1). The purpose of the structured interview was to determine the medical problems underlying the reported chest wall abnormalities. We sought information on 1) deformations of the chest wall that included asymmetric chest wall, pectus excavatum, pectus carinatum, completely or partially missing ribs, deformation of the breast, muscular abnormalities, or other deformations of the chest wall or ribs; 2) deformations of the spine including scoliosis, hyperkyphosis, hyperlordosis, or other deformations of the spine; 3) scars on the chest wall. We also asked about the impact of chest wall abnormalities on daily life which could include general complaints as well as cosmetic problems, respiration problems, flexibility impairments, pain because of the chest wall abnormalities, and impairment in activities of daily living. Finally, we asked whether medical attention—consultation with a physician, diagnostic investigations, operations, and physiotherapy—had been sought. The questionnaire used for the interview is available as supplementary material in its original form in German and as an English translation. The Ethics Committee of the Canton of Bern approved the SCCR and the SCCSS (KEK-BE: 166/2014), and the Swiss Childhood Cancer Survivor Study is registered at ClinicalTrials.gov (identifier: NCT03297034).

Covariates: demographic and cancer-related characteristics

We obtained cancer characteristics from the SCCR including age at diagnosis, year of diagnosis, cancer diagnosis according to the International Classification of Childhood Cancer, 3rd edition [17], and details on radiotherapy, surgery, and chemotherapy. We combined total body irradiation, mantle field radiation, and radiation to the thorax, lungs, mediastinum, or thoracic spine to thoracic radiotherapy (yes/no). Surgery to the chest (yes/no) included the clavicles, scapulae and ribs, tumor excision from soft tissue on thorax, thoracic muscles, thoracic spine, and tumor or lymph node biopsies on the chest wall.

Statistical analysis

We reported prevalence of chest wall abnormalities overall and stratified by sex, age at cancer diagnosis (0–5; 6–10; 11–15; 16–20), years of diagnosis (1976–1990; 1991–2005), cancer diagnosis (leukemia; lymphoma; CNS tumor; other tumors), and cancer treatment (thoracic radiotherapy (yes, no); surgery to the chest (yes, no); any chemotherapy (yes, no)). We identified demographic and cancer-related risk factors for chest wall abnormalities using univariable and multivariable logistic regression. All analyses were done in Stata (Version 14; Stata Corporation, Austin, TX).

Systematic literature review

We conducted a literature review searching for relevant articles in the two bibliographic databases PubMed and Embase Ovid, last updated December 31st 2019. Both databases were searched using thesaurus terms (MeSH, Emtree) and textwords. We applied restrictions to language and searched studies on humans only, and excluded from the search conference abstracts, letters to the editor, and editorials. To retrieve further relevant publications, we checked the reference lists of studies included and added Google scholar for a full-text search. An information specialist from the University Library of Bern was consulted to set up the search strategies in order to ensure optimal data acquisition. The search results were screened in two steps by two independent reviewers (RK, CL) and assessed according to relevance and eligibility criteria (PRISMA flow diagram). We excluded articles on deformations of the spine (kyphosis, kyphoscoliosis, hyperlordosis, and scoliosis), as this was not the main focus of this project. Additional articles were searched by screening the reference list of suitable systematic reviews found in the two databases. For details on search strategies and search platforms, see Supplementary Text and Supplementary figure S3.

Results

Prevalence and risk factors of chest wall abnormalities

Among the 2382 survivors who participated in the SCCSS, 2% (48/2, 382) reported a chest wall abnormality (95% confidence interval [95%CI] 1.5–2.7). Male survivors were more often affected (2.5, 95%CI 1.8–3.5) than females (1.4, 95%CI 0.8–2.3) (Table 1). Median age at study was 31 years (interquartile range [IQR] 25–38) and survivors who were older at cancer diagnosis (16–20 years, 4.2, 95%CI 2.2–7.9) had a higher prevalence of chest wall abnormalities compared to those who were younger. Prevalence did not change over time, being 2 and 2.1% in the periods of 1976–1990 and 1991–2005. When comparing underlying diagnoses, chest wall abnormalities were most frequently reported by survivors of lymphoma (3.7, 95%CI 2.3–6.0) and CNS tumors (3.8, 95%CI 2.2–6.4), but rarely by participants treated for leukemia (0.6, 95%CI 0.2–1.5). Nearly 8% of survivors treated with surgery to the chest and 6% treated with thoracic radiotherapy reported a chest wall abnormality.
Table 1

Characteristics of Swiss childhood cancer survivors overall and of those reporting chest wall abnormalities

OverallN = 2382(100%)Survivors reporting chest wall abnormalitiesN = 48(2.0, 95%CI 1.5–2.7)
n%an%b(95%CI)
Sex
 Female111146.6%161.4%(0.8–2.3)
 Male127153.4%322.5%(1.8–3.5)
Age at diagnosis (years)
 0–5110846.5%201.8%(1.2–2.8)
 6–1052121.9%71.3%(0.6–2.8)
 11–1554022.7%122.2%(1.3–3.9)
 16–202138.9%94.2%(2.2–7.9)
Median (IQR) age at study (years)31.1(24.6–38.2)32.1(25.8–38.1)
Year of diagnosis
 1976–199084535.5%182.1%(1.3–3.4)
 1991–2005153764.5%302.0%(1.4–2.8)
Diagnosis
 I: Leukemia77332.5%50.6%(0.2–1.5)
 II: Lymphoma42817.9%163.7%(2.3–6.0)
 III: CNS tumor34514.5%133.8%(2.2–6.4)
 IV–XII: Other tumors83635.1%141.7%(1.0–2.8)
Thoracic radiotherapy c
 No207587.1%311.5%(1.1–2.1)
 Yes30712.9%175.5%(3.5–8.7)
Surgery to the chest d
 No229096.1%411.8%(1.3–2.4)
 Yes923.9%77.6%(3.7–15.2)
Any chemotherapy
 No41417.4%61.4%(0.7–3.2)
 Yes196882.6%422.1%(1.6–2.9)

Abbreviations: CI Confidence interval, N Number

a Column percentages are given

b Row percentages are given

c Including the following radiation fields: total body irradiation, mantle field, thorax, lungs, mediastinum, or thoracic spine

d Including surgery to clavicle, scapulae and ribs, tumor excision from soft tissue on thorax, muscles on thorax, spine of thorax, and tumor or lymph node biopsy on the chest wall

Characteristics of Swiss childhood cancer survivors overall and of those reporting chest wall abnormalities Abbreviations: CI Confidence interval, N Number a Column percentages are given b Row percentages are given c Including the following radiation fields: total body irradiation, mantle field, thorax, lungs, mediastinum, or thoracic spine d Including surgery to clavicle, scapulae and ribs, tumor excision from soft tissue on thorax, muscles on thorax, spine of thorax, and tumor or lymph node biopsy on the chest wall In a multivariable regression, the following factors remained independently associated with chest wall abnormalities: male sex (odds ratio [OR] 1.8, 95%CI 1.0–3.3), older age at cancer diagnosis (OR 2.5, 95%CI 1.0–6.1), lymphoma (OR 3.8, 95%CI 1.2–11.4), CNS tumor (OR 9.5, 95%CI 3.0–30.1), thoracic radiotherapy (OR 2.0, 95%CI 1.0–4.2), surgery to the chest (OR 4.5, 95%CI 1.8–11.5), and chemotherapy (OR 2.9, 95%CI 1.0–8.1) (Table 2).
Table 2

Demographic and cancer-related risk factors for chest wall abnormalities in Swiss childhood cancer survivors

Total N = 2382Chest wall abnormalities (n = 48)
ORcrudea(95%CI)PbORadjc(95%CI)Pc
Sex0.0590.062
 FemaleRef.Ref.
 Male1.8(1.0–3.2)1.8(1.0–3.3)
Age at diagnosis (years)0.1250.017
 0–5Ref.Ref.
 6–100.7(0.3–1.8)0.5(0.2–1.2)
 11–151.2(0.6–2.5)0.7(0.3–1.6)
 16–202.4(1.1–5.3)2.5(1.0–6.1)
Year of diagnosis0.7680.602
 1976–1990Ref.Ref.
 1991–20050.9(0.5–1.7)0.8(0.5–1.6)
Diagnosis< 0.001< 0.001
 I: LeukemiaRef.Ref.
 II: Lymphoma6.0(2.2–16.4)3.8(1.2–11.4)
 III: CNS tumor6.0(2.1–17.0)9.5(3.0–30.1)
 IV–XII: Other tumors2.6(0.9–7.3)2.1(0.7–6.1)
Thoracic radiotherapy d< 0.0010.058
 NoRef.Ref.
 Yes3.9(2.1–7.1)2.0(1.0–4.2)
Surgery to the chest e0.0020.004
 NoRef.Ref.
 Yes4.5(2.0–10.4)4.5(1.8–11.5)
Any chemotherapy0.3480.029
 NoRef.Ref.
 Yes1.5(0.6–3.5)2.9(1.0–8.1)

Abbreviations: CI Confidence interval, OR Odds ratio, N Number, P P-value

a Odds ratio from univariable logistic regression analysis

bP-values calculated from likelihood-ratio tests comparing survivors with and without chest wall abnormality

c Odds ratio from multivariable logistic regression analysis, model adjusted for all factors shown

d Including the following radiation fields: total body irradiation, mantle field, thorax, lungs, mediastinum, or thoracic spine

e Including surgery to clavicle, scapulae and ribs, tumor excision from soft tissue on thorax, muscles on thorax, spine of thorax, and tumor or lymph node biopsy on the chest wall

Demographic and cancer-related risk factors for chest wall abnormalities in Swiss childhood cancer survivors Abbreviations: CI Confidence interval, OR Odds ratio, N Number, P P-value a Odds ratio from univariable logistic regression analysis bP-values calculated from likelihood-ratio tests comparing survivors with and without chest wall abnormality c Odds ratio from multivariable logistic regression analysis, model adjusted for all factors shown d Including the following radiation fields: total body irradiation, mantle field, thorax, lungs, mediastinum, or thoracic spine e Including surgery to clavicle, scapulae and ribs, tumor excision from soft tissue on thorax, muscles on thorax, spine of thorax, and tumor or lymph node biopsy on the chest wall

Telephone interviews

Among the 48 survivors who reported chest wall abnormalities, 25 survivors were available for interview and 20 participated (80%) (Supplementary figure S1). Of the 20 interviewed, 18 were confirmed to have a chest wall abnormality (Table 3). When asked in more detail, 85% (17/20) described thoracic wall deformities, 60% (12/20) a deformation of the spine, and 70% (14/20) scars on the chest wall. Most survivors (80%; 16/20) reported multiple problems (Fig. 1 and Table 3). Thoracic wall deformities included pectus excavatum (n = 4), pectus carinatum (n = 2) and unspecified thoracic asymmetries (n = 6), missing or deformed ribs (n = 7), and deformation of the breasts (n = 1). Deformation of the spine included scoliosis (n = 7), hyper kyphosis (n = 4), and hyper lordosis (n = 3).
Table 3

Impact of chest wall abnormalities on the daily life of survivors, and medical attention required because of chest wall abnormality

N = 20Proportion (%)
Impact of chest wall abnormalities on daily life
 Any impact1365%
  Respiration840%
  Flexibility735%
  Activities of daily living630%
  Cosmetic630%
  Pain630%
Required medical attention because of chest wall abnormality
 Any medical attention1575%
  Consultation a1470%
   1 specialist visited1050%
    > 1 specialist visited420%
  Diagnostic investigation b945%
   Chest X-ray630%
   Chest X-ray + lung function test315%
  Operations15%
  Physiotherapy630

Abbreviations: N Number; Respiration, any respiratory impairment; Flexibility, impairment of flexibility; Activities of daily living, inability or problems when performing activities of daily living such as housekeeping; Cosmetic, disturbed by the cosmetic appearance of the chest wall abnormality; Pain, any pain because of the chest wall abnormality; Consultation, ever consulted a medical doctor because of the chest wall abnormality; Diagnostic investigation, had further diagnostic testing because of the chest wall abnormality (e.g., chest x-ray, lung function tests); Operations, had an operation because of the chest wall abnormality; Physiotherapy, visited physical therapy because of the chest wall abnormalities

a Survivors reported consultations with: general practitioner n = 5, pediatric oncologist n = 4, oncologist n = 1, orthopedist n = 3, chiropractor n = 1, surgeon n = 1, sports physician n = 1, rheumatologist n = 1

Fig. 1

Proportional Venn diagram showing reported types and overlap of chest wall abnormalities in childhood cancer survivors in the telephone interview

Impact of chest wall abnormalities on the daily life of survivors, and medical attention required because of chest wall abnormality Abbreviations: N Number; Respiration, any respiratory impairment; Flexibility, impairment of flexibility; Activities of daily living, inability or problems when performing activities of daily living such as housekeeping; Cosmetic, disturbed by the cosmetic appearance of the chest wall abnormality; Pain, any pain because of the chest wall abnormality; Consultation, ever consulted a medical doctor because of the chest wall abnormality; Diagnostic investigation, had further diagnostic testing because of the chest wall abnormality (e.g., chest x-ray, lung function tests); Operations, had an operation because of the chest wall abnormality; Physiotherapy, visited physical therapy because of the chest wall abnormalities a Survivors reported consultations with: general practitioner n = 5, pediatric oncologist n = 4, oncologist n = 1, orthopedist n = 3, chiropractor n = 1, surgeon n = 1, sports physician n = 1, rheumatologist n = 1 Proportional Venn diagram showing reported types and overlap of chest wall abnormalities in childhood cancer survivors in the telephone interview We also asked survivors whether the chest wall abnormalities affected their daily life and if they had sought medical attention. Among the 20 survivors interviewed, 13 survivors said that the chest wall abnormality affected respiration, flexibility, and activities of daily life, caused cosmetic problems, or pain (Table 3). Fifteen survivors had sought medical attention. Fourteen consulted a doctor (10 visited one specialist only and four visited multiple specialists). Specialists included general practitioners, pediatric oncologists, orthopedists, chiropractors, surgeons, sport physicians, or rheumatologists. Nine survivors underwent diagnostic testing, six had a chest x-ray only and three a chest x-ray and lung function tests. One survivor needed surgery and six received physiotherapy (Table 3).

Literature review

Of the 2167 potentially relevant articles identified, we excluded 1935 articles after screening of title and abstracts, leaving 244 articles for full-text screening. Of those, we excluded a further 232 articles that did not meet the inclusion criteria (Supplementary figure S3). We summarize the remaining in Table 4. Among these, only two investigated an unselected cohort of survivors with regard to cancer diagnosis and treatment [11, 12]. Both used postal questionnaires (the Swiss and North American Childhood Cancer Survivor Studies) and found a prevalence of chest wall abnormalities of 2.0% [12] and 1.3% [11]. Six studies focused on survivors of selected cancer diagnoses [1–4, 9, 10]. Lucas et al. studied 23 survivors of chest wall sarcoma in the USA and found that one survivor (4%) had a ctCAE (Common Terminology Criteria for Adverse Events) Grade IV bone abnormality of the chest [1]. Utriainen et al. found that one of 21 (5%) Finnish survivors of high-risk neuroblastoma treated with hematopoietic stem cell transplantation had a sternal asymmetry [9]. Huang et al. found that, in the North American Childhood Cancer Survivor Study of 1653 survivors, 15 (0.4%) had a chest wall abnormality [10]. Perwein et al. studied 16 stage 4 neuroblastoma survivors and found that, of four (25%) with musculoskeletal late effects, one (6%) had an asymmetric pectus carinatum [2]. Tröbs et al. reported chest wall deformity in three (6%) of 49 German Wilms tumor survivors [3]. Heaston et al. studied 25 US Wilms tumor survivors and found radiographic evidence of abnormal skeletal development in 24 (96%) and hypoplasia of the pelvis and/or thorax in 13 (52%) [4].
Table 4

Literature summary of systematic review on chest wall abnormalities in childhood cancer survivors

First author, year, countryTreatment eraInclusion criteriaType of outcome assessmentSample Size (n)Age at diagnosis in yearsYears of follow-upChest wall abnormality
Definitionn%
Study sample unselected with regard to cancer diagnosis and treatment
 Kasteler 2017, CH [12]1997–2005Childhood cancer Survived 5 years from diagnosis ≥16 years old at surveyPostal questionnaire1894Median: 9 IQR: 4–14

Median: 18

IQR: 13–23

Chest wall abnormalities
- Ever in life422.2%
- After cancer diagnosis382.0%
 Mertens 2001, USA [11]1970–1986Childhood cancer Survived 5 years from diagnosisPostal questionnaire12,390Range: 0–21n.m.Chest wall abnormalities overall1581.3%
- Before diagnosis220.2%
- Diagnosis to end of treatment390.3%
- During first 5 years after end of treatment210.2%
- > 5 years after end of treatments360.3%
Studies focusing on selected diagnoses
 Lucas 2017, USA [1]10/06/ 2003–11/06/2011Chest wall sarcoma survivorsCT or chest x-ray23Median: 12.5 Range: 3.6–20.6Median: 9.25Bone abnormalities
- ctCAE Grade IV (rib fracture with non-union resulting in pseudoarthrosis)14%
 Utriainen2017, FI [9]1980–2000

High risk neuroblastoma survivors

Treated with HSCT

Questionnaire, interview, hospital records, Physical examination21

Median: 1.7

Range: 0.2–3.9

Median: 20

Range: 13–28

Skeletal complications

- Sternal asymmetry

15%
 Huang2013, USA [10]1970–1986CNS tumor survived 5 years from diagnosisPostal questionnaire1653

Median: 7.6

Range: 0–21

Median: 18.5

Range: 3.3–33.9

Kyphosis, scoliosis and/or acquired deformity of the chest or ribs150.4%
 Perwein 2011, A [2]1984–09/2009Stage 4 Neuroblastoma Regular presentation in follow-up programMedical records review16

Median: 1.8

Range: 0.2–10.7

Median: 4.3

Range: 0.4–23.2

Musculoskeletal late effects425%
- Asymmetric pectus carinatum16.3%
 Tröbs 2001, D 301/1974–12/1988Wilms tumorMedical records review49Median: 2.6n.mChest wall deformity36%
 Heaston 1979, USA [4]01/1954–12/1975Wilms tumor Survived 4 years Megavoltage therapy Detailed medical data and serial radiographs availableMedical records review25

Mean: 3.5

Range: 0.1–9.3

Mean: 9.8

Range: 4–18

Axial Skeletal alternation (megavoltage)
- Radiographic evidence of abnormal skeletal development2496%
Extra axial skeletal alterations
- Hypoplasia of the pelvis and/or thorax1352%
Studies focusing on specific cancer treatments
 Venkatramani 2013, USA [8]1999–2009Childhood cancer Radiotherapy to the lungs without total body irradiation or whole lung irradiationMedical records review109

Median: 13.4

Range: 0.01–19.9

Median: 2.5

Range: 0.2–9

Chest wall abnormality1110%
- Hypoplasia of chest wall11%
 Pintér 2003, HU [5]01/01/1975–31/12/1983Childhood cancer Operated for solid malign tumor excluding retinoblastomas and CNS tumorsPersonal interviews, questionnaires79

N = 17 < 1 year old

N = 62 < 29 days old:

Mean: 20

Range: 16–25

Subgroup analysis per treatment group
Surgical intervention (n = 15)
- Thoracic deformity427%
- Scar formation resulting in psychological problems1280%
Multimodal therapy (surgical, chemo-, and radiotherapy, n = 64)
- Skin lesion following radiotherapy23%
- Muscular deformity711%
- Bone morbidity (underdevelopment)58%
- Decreased physical ability to work35%
- Thoracic deformity46%
- Breast underdevelopment711%
- Scar formation resulting in psychological problems1219%
 Butler 1990, USA [6]1970–1987

Childhood cancer Survived to the age of skeletal maturity (14 years for females and 16 years for males)

One year follow-up after irradiation

Radiation to spine and/or extremities

Medical records review143

Mean: 8.3

Range: 0.1–12.9

Mean: 9.9

Range: 2–18

Chest and rib deformity5136%
In girls: breast asymmetry, none had treatment, although there were severe cosmetic deformities735%
Significant pain at the radiation sites (low back pain most common)2316.1%
 Taylor 1997, UK [7]1980–1986Childhood Wilms tumor Abdominal radiotherapy Assessment of late effects through physician availableFollow-up forms filled by doctors138

N = 50 < 3 years old

N = 88 ≥ 3 years old

Median: 10.6Musculoskeletal late effects 8 of 27 described as ‘mild’2719.6%
- Asymmetry139.4%
- Hypoplasia64.3%
- Breast asymmetry10.7%
- Rib hypoplasia10.7%

Abbreviation: CNS Central nervous system, CT Computer tomography, ctCAE Common terminology criteria for adverse events; n.m Not mentioned

Literature summary of systematic review on chest wall abnormalities in childhood cancer survivors Median: 18 IQR: 13–23 High risk neuroblastoma survivors Treated with HSCT Median: 1.7 Range: 0.2–3.9 Median: 20 Range: 13–28 Skeletal complications - Sternal asymmetry Median: 7.6 Range: 0–21 Median: 18.5 Range: 3.3–33.9 Median: 1.8 Range: 0.2–10.7 Median: 4.3 Range: 0.4–23.2 Mean: 3.5 Range: 0.1–9.3 Mean: 9.8 Range: 4–18 Median: 13.4 Range: 0.01–19.9 Median: 2.5 Range: 0.2–9 N = 17 < 1 year old N = 62 < 29 days old: Mean: 20 Range: 16–25 Childhood cancer Survived to the age of skeletal maturity (14 years for females and 16 years for males) One year follow-up after irradiation Radiation to spine and/or extremities Mean: 8.3 Range: 0.1–12.9 Mean: 9.9 Range: 2–18 N = 50 < 3 years old N = 88 ≥ 3 years old Abbreviation: CNS Central nervous system, CT Computer tomography, ctCAE Common terminology criteria for adverse events; n.m Not mentioned Four studies focused on specific cancer treatments only [5-8]. Venkatramani et al. found that, of 109 US survivors treated with radiotherapy to the lungs without total body irradiation or whole lung irradiation, eleven (10%) had a chest wall abnormality—of those 11, one (1%) had hypoplasia of the chest wall [8]. Pintér et al. studied survivors who were operated on for solid malign tumors in Hungary [5]. In those with surgical treatment only (n = 15), four (27%) had a thoracic deformity and twelve (80%) had scar formation resulting in psychological problems. In those with multimodal therapy (n = 64), two (3%) had skin lesions following radiotherapy, seven (11%) had a muscular deformity, five (8%) had bone morbidity (underdevelopment), three (5%) had a decreased physical ability to work, four (6%) had a thorax deformity, seven (11%) had breast underdevelopment, and twelve (19%) had scar formation resulting in psychological problems. Butler et al. found that, of 143 US survivors 1 year after irradiation to the spine and/or extremities, 51 (36%) had a chest and rib deformity and 23 (16.%) had significant pain at the radiation sites [6]. Taylor et al. found that, out of 138 survivors of Wilms tumor after abdominal radiotherapy, 27 (19%) had musculoskeletal late effects, thirteen (9%) had asymmetry, six (4%) hypolplasia, one (0.7%) breast asymmetry, and one (0.7%) rib hypoplasia [7]. Studies that focused on selected outcomes or treatments reported a higher prevalence of chest wall abnormalities than studies based on unselected survivor cohorts (Table 4).

Discussion

This is the first study to describe self-reported chest wall abnormalities in an unselected, representative sample of childhood cancer survivors in detail, and to validate answers in a structured interview. Two percent of all survivors reported a chest wall abnormality. We found a broad range of problems that were summarized as chest wall abnormalities. More than half of interviewed survivors were affected in their daily lives and three quarters required medical attention. A strength of this study is that we clarified types of chest wall abnormalities and their impact on daily life by directly interviewing survivors. Survivors could explain their problems and we could inquire about the impact of their chest wall abnormalities. We were able to reach 80% of eligible survivors who had reported a chest wall abnormality in the SCCSS questionnaire. Participants did not differ from nonparticipants (results not shown) and a previous study concluded that response bias in the SCCSS did not markedly influence prevalence estimates [18]. A limitation of this study is that we were not able to validate chest wall abnormalities in survivors with medical exams or x-rays. A medical examination or chest x-ray would have helped to further quantify type and severity of the reported problems. The prevalence of chest wall abnormalities in this study and in a previously published study from Switzerland with an overlapping population [12] was only slightly higher than in the North American Childhood Cancer Survivors Study (2.0% versus 1.3%) [11]. These two studies present data with similar methods (questionnaire survey) in an unselected cohort in respect to diagnoses and cancer treatment in either a national or multicenter set up. A further report of the North American Childhood Cancer survivors study on CNS tumor survivors found chest wall abnormalities in 0.4% of survivors—this is lower than in the group of CNS tumor survivors in our study (4%) [10]. Treatment-related factors like the frequency and cumulative dose of thoracic radiotherapy (such as spinal radiation in CNS tumor patients) might differ between countries and help to explain such differences in prevalence of chest wall abnormalities. Other studies and case series focusing on diagnostic subgroups mostly reported higher prevalence of chest wall abnormalities (4–52%) [1–4, 9]. They were all small, with 49 or less participants, and included high-risk tumor survivors who were exposed to intensive multimodal cancer treatment (stage 4 or high-risk neuroblastoma [2, 9]), survivors with tumors on the chest wall (chest wall sarcoma [1]), or diagnosed a long time ago, where radiotherapy and surgical approaches were far more invasive than today which in general sets survivors at higher risk of developing late effects [3, 4]. Four other studies focused on survivors of specific cancer treatments such as radiotherapy to the lungs [8], spine/extremities [6], or abdomen [7], or surgery of solid malign tumors [5] reported chest wall abnormalities in 1–36% of participants. In our study, those treated with thoracic radiotherapy or surgery to the chest had higher prevalence of chest wall abnormality than those without, reflecting the findings of the other studies. Risk factors for chest wall abnormalities in survivors vary between studies. Our study is the first to report older age at diagnosis (16–20 years) as a risk factor for chest wall abnormalities. Peak bone growth velocity and increase of peak bone mass happen during puberty [19], therefore cancer treatment during this vulnerable time may affect the development of the spine and thoracic wall more severely than treatment earlier in childhood. CNS tumor survivors were most likely to report chest wall abnormalities. CNS tumors are often treated with radiotherapy to the spine, which is another risk factor identified in our study (OR 2.0; 95%CI 1.0–4.2), in the North American Childhood Cancer Survivor Study (rate ratio 5.0) [11], and in other studies [5-8]. Also, CNS tumor survivors often suffer from comorbidities that include small stature, functional deficits, endocrine diseases, fatigue, and psychological problems [20], which might lead to a higher subjective burden of chest wall abnormalities compared to other survivor groups. We could validate chest wall abnormalities in 18 of 20 survivors who indicated a chest wall abnormality in the SCCSS questionnaire. Two survivors had scars only (which they reported as chest wall abnormalities) and 12 had both scars and chest wall abnormalities. This suggests that not all survivors understood the term “chest wall abnormality” as was intended by the questionnaire. We suggest that future questionnaires describe chest wall abnormalities in more detail or use open questions to further assess the type of chest wall abnormality. For physicians involved in follow-up care of childhood cancer survivors, awareness of chest wall abnormalities should be raised and clinical examinations performed to quantify the extent of individual problems and limitations. Many participants were affected in daily life by chest wall abnormalities, which reflects the severity of this rare late effect after childhood cancer treatment. The most common complaints were impaired flexibility and physical fitness. An interdisciplinary treatment approach could help improve these issues. Early physiotherapy could be used in survivors at risk of developing chest wall abnormalities to improve late functional outcomes and might also reduce pain.

Conclusion

In conclusion, this study suggests that, even though chest wall abnormalities are rare in the entire childhood cancer survivor population, they have a considerable impact on survivors’ lives. Physicians should pay close attention to these problems during follow-up care. Additional file 1: Figure S1. Study flowchart for the participation in the telephone interview on chest wall abnormalities in the Swiss Childhood Cancer Survivor Study. Figure S2. Original question in A) German, B) French) and C) English translation of original question for adults on pulmonary health in the SCCSS questionnaire. Supplementary Text. Figure S3. Prisma flow diagram of the article screening process. Additional file 2. Additional file 3.
  20 in total

1.  A 23-year experience with malignant renal tumors in infancy and childhood.

Authors:  R B Tröbs; M Hänsel; T Friedrich; J Bennek
Journal:  Eur J Pediatr Surg       Date:  2001-04       Impact factor: 2.191

2.  International Classification of Childhood Cancer, third edition.

Authors:  Eva Steliarova-Foucher; Charles Stiller; Brigitte Lacour; Peter Kaatsch
Journal:  Cancer       Date:  2005-04-01       Impact factor: 6.860

3.  Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue.

Authors:  P Utriainen; A Vatanen; S Toiviainen-Salo; U Saarinen-Pihkala; O Mäkitie; K Jahnukainen
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

4.  Morbidity from abdominal radiotherapy in the First United Kingdom Children's Cancer Study Group Wilms' Tumour Study. United Kingdom Children's Cancer Study Group.

Authors:  R E Taylor
Journal:  Clin Oncol (R Coll Radiol)       Date:  1997       Impact factor: 4.126

Review 5.  Late effects of therapy for pediatric brain tumor survivors.

Authors:  Christopher D Turner; Celiane Rey-Casserly; Cori C Liptak; Christine Chordas
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

6.  Correlation of clinical and dosimetric factors with adverse pulmonary outcomes in children after lung irradiation.

Authors:  Rajkumar Venkatramani; Sunil Kamath; Kenneth Wong; Arthur J Olch; Jemily Malvar; Richard Sposto; Fariba Goodarzian; David R Freyer; Thomas G Keens; Leo Mascarenhas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-05-29       Impact factor: 7.038

7.  Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study.

Authors:  Ann C Mertens; Yutaka Yasui; Yan Liu; Marilyn Stovall; Ray Hutchinson; Jill Ginsberg; Charles Sklar; Leslie L Robison
Journal:  Cancer       Date:  2002-12-01       Impact factor: 6.921

8.  Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project.

Authors:  Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer
Journal:  Med Pediatr Oncol       Date:  2002-04

9.  No evidence of response bias in a population-based childhood cancer survivor questionnaire survey - Results from the Swiss Childhood Cancer Survivor Study.

Authors:  Corina S Rueegg; Micòl E Gianinazzi; Gisela Michel; Marcel Zwahlen; Nicolas X von der Weid; Claudia E Kuehni
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

10.  Late toxicity and outcomes following radiation therapy for chest wall sarcomas in pediatric patients.

Authors:  John T Lucas; Israel Fernandez-Pineda; Christopher L Tinkle; Michael W Bishop; Sue C Kaste; Rajiv Heda; Andrew M Davidoff; Matthew J Krasin
Journal:  Pract Radiat Oncol       Date:  2017-04-26
View more
  1 in total

1.  Surgical removal of bilateral lung metastases from Wilms tumor via subxiphoid approach video-assisted thoracic surgery: a case report.

Authors:  Longfei Lv; Baohua Yu; Yunpeng Zhai; Huashan Zhao; Rui Guo; Hongxiu Xu; Shisong Zhang
Journal:  Transl Pediatr       Date:  2022-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.